Apollomics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Vebreltinib (APL-101) SPARTA Trial Enrollment Quarterly282.0Target: Complete enrollment for SPARTA Phase 2 multicohort clinical trial
Cash and Cash Equivalents Quarterly3.3MTarget: Secure additional external financing to extend runway beyond Q3 2026
Annual Revenue Annually8.5MTarget: Collect remaining receivables from LaunXP licensing agreement
Watch Items
- Going Concern Status and Cash RunwayTrigger: Cash balance falling below $1.0 million without secured financingAction: Evaluate strategic alternatives, further cost-cutting, or additional related-party bridge loans.
- Vebreltinib U.S. IND Submission for Accelerated ApprovalTrigger: Delay beyond H1 2027Action: Reassess clinical data pooling from SPARTA and PEARL trials and consult with the FDA.
- Nasdaq Listing ComplianceTrigger: Staff determination or minimum bid price warningAction: Maintain active communication with the Nasdaq Listing Qualifications Panel and execute corporate restructuring if necessary.
Research as of 20 Jun 2026